Pliant Therapeutics, Inc. (PLRX)

Market Cap	187.43M
Revenue (ttm)	n/a
Net Income (ttm)	-201.68M
Shares Out	60.85M
EPS (ttm)	-3.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,996,344
Open	3.060
Previous Close	3.010
Day's Range	2.995 - 3.130
52-Week Range	2.430 - 18.000
Beta	1.04
Analysts	Buy
Price Target	14.86 (+382.47%)
Earnings Date	Mar 7, 2025

About PLRX

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company’s lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of αvß6 and αvß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of αvß1 for the treatment of liver f...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 3, 2020
• Employees: 158
• Stock Exchange: NASDAQ
• Ticker Symbol: PLRX
• Website: https://pliantrx.com

Financial Performance

In 2023, Pliant Therapeutics's revenue was $1.58 million, a decrease of -83.69% compared to the previous year's $9.69 million. Losses were -$161.34 million, 30.8% more than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for PLRX stock is "Buy." The 12-month stock price forecast is $14.86, which is an increase of 382.47% from the latest price.

Price Target

$14.86

(382.47% upside)

Analyst Consensus: Buy